Two New Zn(II)/Cd(II) Complexes: Luminescent Properties and Treatment Activity on Cardiovascular Disease

Two new supramolecular frameworks, namely [Zn(HBTC)(H2O)2]n·n(MA) (1) and {[Cd(OBDC)2(MA)(H2O)Cl](HMA)3(H2O)10(DMA)}n (2) (H3BTC = 1,3,5-benzenetricarboxylic acid, H2OBDC = phthalic acid, MA = melamine, DMA = N,N’-dimethylacetamide), have been solvothermally prepared. In addition, the solid-state luminescent properties of 1–2 at room temperature was discussed in this article as well. Their application values on the cardiovascular disease treatment were explored and we also discussed the corresponding mechanism simultaneously. Firstly, the IL-6 and IL-18 released into the plasma was measured with indicated ELISA assay. Besides, the real time RT-PCR was also performed, while activation levels of AMPK signaling pathway was determined after compound treatment.